SCHEMBL1715904

SCHEMBL1715904

Cc1ccc(NC(C#N)(CCl)CCl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
CYP2A6 P11509 1/20 0.39
MAPT P10636 3/20 0.38
POLB P06746 1/20 0.33
LMNA P02545 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.32
NPC1 O15118 4/20 0.32
HTT P42858 3/20 0.32
RAB9A P51151 2/20 0.32
CSNK1A1 P48729 1/20 0.32
CSNK1D P48730 1/20 0.32
GSK3B P49841 1/20 0.32
CSNK1G2 P78368 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GAA P10253 1/20 0.32
DHODH Q02127 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715946 0.72 ALDH1A1 (0.39) ALDH1A1CYP2A6MAPTPOLBLMNA
SCHEMBL193237 0.72 MAPT (0.39) ALDH1A1CYP2A6MAPTPOLBLMNA
SCHEMBL1723351 0.69 MAPT (0.41) ALDH1A1CYP2A6MAPTPOLBLMNA
SCHEMBL5983235 0.64 NPC1 (0.48) ALDH1A1MAPTPOLBLMNAHPGD
SCHEMBL8395286 0.63 MAPT (0.58) ALDH1A1CYP2A6MAPTPOLBKDM4E
P-Xylene SCHEMBL11344217 0.62 ACHE (0.50) ALDH1A1CYP2A6MAPTLMNANPC1
SCHEMBL2722652 0.62 MAPT (0.50) MAPTPOLBLMNAHPGDNPC1
SCHEMBL1248173 0.62 TDP1 (0.44) MAPTPOLBLMNAHPGDNPC1
SCHEMBL10804520 0.62 ALDH1A1 (0.46) ALDH1A1CYP2A6MAPTPOLBLMNA
SCHEMBL10694580 0.61 ALDH1A1 (0.73) ALDH1A1CYP2A6HPGDCSNK1A1CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333385-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-30 US disclosed
US-20240132452-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-04-25 US disclosed
CN-116003328-A Diaryl hydantoin compounds 加利福尼亚大学董事会 2023-04-25 CN disclosed
US-20230109968-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-13 US disclosed
CN-110003114-B Diarylhydantoin compounds 加利福尼亚大学董事会 2023-01-17 CN disclosed
EP-3970721-A1 DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-03-23 EP disclosed
US-20210238145-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-05 US disclosed
US-20200079741-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-03-12 US disclosed
US-20190210974-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-07-11 US disclosed
US-20180086718-A1 Diarylhydantoin Compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-03-29 US disclosed
EP-2561871-A1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer The Regents of The University of California (US) 2013-02-27 EP disclosed
US-20130034501-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-02-07 US disclosed
US-20120295944-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-22 US disclosed
US-8183274-B2 Treatment of hyperproliferative disorders with diarylhydantoin compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-22 US disclosed
EP-2444085-A1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer The Regents of The University of California (US) 2012-04-25 EP disclosed
EP-1893196-B1 DIARYLHYDANTOIN COMPOUND UNIV CALIFORNIA (US) 2012-01-18 EP disclosed
US-20100210665-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-08-19 US disclosed
US-20100172975-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-08 US disclosed
US-7709517-B2 N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-05-04 US disclosed
US-20070004753-A1 N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132452-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885
US-20120295944-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS CDK4, CCNH, VHL ALDH1A1 1580/4885CYP2A6 2766/4885MAPT 3438/4885
US-20180086718-A1 Diarylhydantoin Compounds BPHL, AR, SHBG ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885
US-20070004753-A1 N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer AR, BRDT, GNRHR ALDH1A1 1572/4885CYP2A6 1209/4885MAPT 3598/4885
US-20100172975-A1 TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS CDK4, CCNH, VHL ALDH1A1 1580/4885CYP2A6 2766/4885MAPT 3438/4885
US-20250333385-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885
US-20190210974-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885
US-20200079741-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885
US-20130034501-A1 DIARYLHYDANTOIN COMPOUNDS FAP, LEF1, LPXN ALDH1A1 550/4885CYP2A6 332/4885MAPT 4094/4885
US-20230109968-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885
US-20210238145-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885
US-20100210665-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.